Literature DB >> 8370765

Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis.

M L Vieira1, S Caillat-Zucman, P Gajdos, S Cohen-Kaminsky, A Casteur, J F Bach.   

Abstract

HLA association with myasthenia gravis (MG) has been studied in a series of 114 patients using class I and class II genotyping after PCR amplification. Positive association was found with DR3, particularly in women (RR = 2.6) and in early MG onset (RR = 3.4). DRB1, DRB3, DQB1, DQA1 and B (B8 and B18) genotyping revealed that the association was predominantly with the B8 DRB1*03 DRB3*0101 DQB1*0201 DQA1*0501 ancestral haplotype. This haplotype frequency was also increased in patients with thymic hyperplasia (RR = 3.5) and was greatly reduced in patients with thymoma (RR = 0.35). Sixteen out of 48 patients carrying this 8.1 ancestral haplotype showed absence of B8 (n = 4) or of DR3 (n = 12). HLA class II genotyping further revealed the existence of two other significant associations. MG was positively associated with the DQB1*0604 allele (RR = 3.4), particularly in patients with thymoma (RR = 5.7). Furthermore, the disease was negatively associated with DR1 in females (RR = 0.32). These data suggest that MG is placed under the control of at least three distinct genes: (1) a class II predisposing gene in the 8.1 ancestral haplotype; (2) a thymoma-associated class II allele on the DQB1*0604 haplotype; and (3) a protective allele DR1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370765     DOI: 10.1016/0165-5728(93)90021-p

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors:  Patrice Nancy; Sonia Berrih-Aknin
Journal:  Endocrinology       Date:  2005-01-20       Impact factor: 4.736

2.  beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG).

Authors:  B Y Xu; D Huang; R Pirskanen; A K Lefvert
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort.

Authors:  Maria Salvado; Jose Luis Caro; Cecilia Garcia; Francesc Rudilla; Laura Zalba-Jadraque; Eva Lopez; Elia Sanjuan; Josep Gamez; Jose Manuel Vidal-Taboada
Journal:  Neurol Sci       Date:  2022-05-06       Impact factor: 3.830

4.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

5.  Identifying alternative hyper-splicing signatures in MG-thymoma by exon arrays.

Authors:  Lilach Soreq; Adi Gilboa-Geffen; Sonia Berrih-Aknin; Paul Lacoste; Ariel Darvasi; Eyal Soreq; Hagai Bergman; Hermona Soreq
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

6.  Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas.

Authors:  M J Kornstein; O Asher; S Fuchs
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

7.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

8.  CCR2-64I and CCR5Delta32 Polymorphisms in Korean Patients with Myasthenia Gravis.

Authors:  Hyun Sook Kim; Dae-Seong Kim; Eun Young Lee; Il-Nam Sunwoo; Young-Chul Choi
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.